Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Virender Kumar · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2022 · $105,638 — PROJECT SUMMARY This K01 application aims to promote the applicant's development to become a multi-disciplinarily trained and independent academic researcher. This application's collective strengths are defined in these 3 major areas: 1) Credentials: PI's application builds upon his productive trac…
Devanand Sarkar · VIRGINIA COMMONWEALTH UNIVERSITY · 2022 · $623,536 — Summary Nonalcoholic steatohepatitis (NASH), the most common cause of chronic liver disease in the Western world and a major global health problem, leads to cirrhosis and hepatocellular carcinoma (HCC). The lack of an optimum therapy mandates better understanding of the molecular pathogenesis of NAS…
FREDERICK D QUINN · UNIVERSITY OF GEORGIA · 2022 · $484,996 — Summary Bacterial and viral respiratory pathogens interact closely with mucosal surfaces. Specialized innate and adaptive mucosal immune systems protect these surfaces and are the first line of defense for the body. One of the more important reasons for the development of mucosal vaccines is the inc…
MICHAEL B ELOWITZ · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2022 · $602,432 — Cell targeting with synthetic sense-and-respond protease circuits Abstract A fundamental challenge in biomedicine is developing therapeutics that can target specific cell populations. Synthetic protein circuits, based on engineered proteins that interact with one another and with endogenous cellular…
SEBASTIAN JOYCE · VETERANS HEALTH ADMINISTRATION · 2022 — The overarching goal of my research program is to understand the molecular mechanisms of immune surveillance mediated by tissue-resident memory T cells that patrol the mucosal barrier of the lungs to control infectious diseases and cancers. My laboratory is best recognized for its c…
Fekadu Kassie · UNIVERSITY OF MINNESOTA · 2022 · $345,230 — PROJECT SUMMARY Lung cancer is the leading cause of cancer-related death in the United States. About 90% of lung cancer cases are associated with genetic/epigenetic changes induced by tobacco smoke (TS). Although all types of lung cells could be affected by TS, the effect on stem cells is particular…
WENKE FENG · UNIVERSITY OF LOUISVILLE · 2022 · $531,959 — Numerous studies have reported the efficacy of probiotics for alcohol associated liver disease (ALD). This reflects a strong interest among the scientific and medical communities in identifying alternative or adjunctive approaches for ALD, for which there is no current effective or widely accepted t…
TIMOTHY M GRIFFIN · OKLAHOMA CITY VA MEDICAL CENTER · 2022 — Osteoarthritis (OA) disproportionately affects veterans, resulting in more pain and functional limitations compared to the general population. No disease-modifying treatments exist for OA, and current pain medications (e.g., opioids and NSAIDs) have limited long-term efficacy and adverse side effect…
Jennifer Eileen Adair · FRED HUTCHINSON CANCER CENTER · 2022 · $877,927 — PROJECT SUMMARY / ABSTRACT The quest for an HIV cure remains incomplete, nearly half a century since the onset of the epidemic. Antiretroviral drug cocktails can suppress HIV infection, but suffer in their success owing to side effects and limitations in access and compliance. Injection of broadly n…
Xiaowei Dong · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2022 · $366,352 — Project Summary/Abstract Bioavailability enhancement technologies for insoluble drugs represent incremental progress, but no breakthrough oral drug technologies have been identified in the past three decades. Lipid-based drug delivery systems (LBDDS) are considered as a well-established, very import…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $535,205 — ABSTRACT The use of RNA technologies to specifically target genetic alterations in tumor cells has shown great potential of becoming a novel therapy modality for cancer treatment. Nevertheless, systemic delivery of RNA agents such as messenger RNA (mRNA) to tumor cells in vivo commonly faces multipl…
John W. Schoggins · UT SOUTHWESTERN MEDICAL CENTER · 2022 · $468,599 — Project Summary Enteroviruses A, B, C, D are important pathogens that can cause a range of diseases including myocarditis, encephalitis, meningitis, conjunctivitis, hand, foot and mouth disease, and acute flaccid myelitis. Disease outcomes can be severe or fatal, particularly in neonates and childre…
Bjoern Markus Reinhard · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · 2022 · $229,758 — Summary The structure of important biomolecules is intrinsically dynamic, and there is an important need for optical tools that can probe the structural dynamics of biopolymers at the single molecule level with high temporal resolution and without limitation in maximum observation time. Dynamic mole…
MARCUS AARON HORWITZ · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $549,664 — Project Summary/Abstract Francisella tularensis is a bacterium that causes tularemia, a disease which, when in its pneumonic form, can be fatal even with appropriate treatment. Due to its low infectious dose, ease of spread by aerosol, and high virulence, F. tularensis is classified as a Tier 1 Sele…
Roy A Mariuzza · UNIV OF MARYLAND, COLLEGE PARK · 2024 · $193,671 — Project Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Elucidating the mechanisms underlying the adaptive immune response to SARS-CoV-2 is crucial for predicting vaccine efficacy and assessing…
Sizun Jiang · BETH ISRAEL DEACONESS MEDICAL CENTER · 2024 · $478,605 — PROJECT SUMMARY/ABSTRACT Distinctive host-pathogen interactions and adaptations are the cornerstones of co-evolution between eukaryotes and their viral pathogens. Given the rapid replication and mutation rates of RNA viruses within their host, understanding these intra-host interactions in their nat…
Joyce Jose · PENNSYLVANIA STATE UNIVERSITY, THE · 2024 · $196,044 — Mosquito-borne alphaviruses such as chikungunya, Mayaro, and Eastern equine encephalitis viruses cause high morbidity and mortality in their mammalian hosts. Alphaviruses are globally distributed arthropod-borne viruses that are enzootic in nature with the potential to disseminate to new geographica…
Thomas Miller Gallagher · LOYOLA UNIVERSITY CHICAGO · 2024 · $192,500 — PROJECT SUMMARY The continuous adaptation of SARS-CoV-2 generates variants of concern (VOC). New VOCs arise independently and outcompete previous ones, consistent with ever increasing viral fitness. Most VOC adaptations reside in the spikes (S), the complex multidomain glycoprotein trimers that bind…
Mark L Baccei · UNIVERSITY OF CINCINNATI · 2024 · $575,744 — Project Summary/Abstract Long-term potentiation (LTP) of primary afferent synapses onto spinal projection neurons (PNs) has been linked to increased pain sensitivity. The timing rules controlling the generation of LTP in adult PNs can be persistently relaxed by neonatal tissue damage, which likely …
Samuel David Stampfer · EMORY UNIVERSITY · 2024 · $181,764 — Project Summary/Abstract Current COVID-19 vaccines fail to induce strong cross-reactive neutralizing antibodies against circulating SARS- CoV-2 variants, which have undergone extensive mutation in the neutralizing epitopes of spike protein. Booster vaccinations with variant-matched vaccines primaril…